Pandemic preparedness: Lessons learnt from H2N2 and H9N2 candidate vaccines

Medical Microbiology and Immunology

Volumn 191, Issue 3-4, 2002, Pages 203-208

  Hehme, Norbert ^a   Engelmann, H ^a   Kunzel W ^a   Neumeier, E ^a   Sanger R ^a  

^a GLAXOSMITHKLINE   (Germany)

Author keywords

Adjuvant; Influenza; Pandemic; Vaccine; Whole virus

Indexed keywords

ALUMINUM; ANTIBODY; ANTIGEN; H2N2 VACCINE; H9N2 VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; EPIDEMIC; FEASIBILITY STUDY; HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SENESCENCE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH PLANNING; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED;

EID: 0036458071     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-002-0147-9     Document Type: Article

References (21)

1. Ada GL, Tannock GA, Hampson AW (1997) Options for the control of influenza, III. Conference report. Vaccine 15:245-247
2. Ambrosch F, Fedson DS (1999) Influenza vaccination in 29 countries. An update to 1997. Pharmaeconomics 16 (Suppl 1):47-54
3. Aymard M, Cox NJ, Dubois G, Ghendon Y, Hannoun C, Hampson A, Haaheim LR, Morgan-Capner P, Saliou P, Tamblyn S (1994) Recommendations of the 7th European meeting on influenza and its prevention. Eur J Epidemiol 10:525-526
4. Beyer WEP, Palache AM, Masurel N, Sprenger MJW (1992) Critical evaluation of parameters to assess the antibody response to influenza vaccination. In: Abstracts of the International Conference on Options for the Control of Influenza, II; Courchevel, France, 1992. Elsevier, Amsterdam, p 70
5. Committee for Proprietary Medicinal Products (1997) Note for Guidance on Harmonization of Requirements for Influenza Vaccines. CPMP/BWP/214/96, circular no. 96-0666:1-22
6. Fedson DS (2001) The epidemiology of influenza vaccination: Implications for global vaccine supply for an influenza pandemic. In: Osterhaus ADME, Cox NJ, Hampson AW (eds) Options for the Control of Influenza, IV. International Congress Series no. 1219. Elsevier Science, Amsterdam, pp 723-731
7. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F (1999) Development of a vero cell-derived influenza whole virus vaccine. Dev Biol Stand 98:101-110
8. Lehmann EL, D'Abrera HJM (1975) Nonparametrics. Statistical Methods Based on Ranks. Holden-Day, San Francisco, pp 5-31, 204-210
9. Lin YP, Shaw V, Gregory K, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N, Hay A (2000) Avian-to-human transmission of H9N2 subtype influenza A viruses. Relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 97:9654-9658
10. Monto AS (1997) Pandemic influenza - Confronting a reemergent threat. J Infect Dis 176 (Suppl 1):S1-S89
11. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF-59 adjuvanted A/Duck/Singapore/97 (H5N3) vaccine - A randomized trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943
12. Parkman PD, Hopps HE, Rastogi SC, Meyer HM (1977) Summary of clinical trials of influenza vaccines in adults. J Infect Dis 136:722-730
13. Peiris M, Yuen KY, Leung KH, Chan KH, Ip PLS, Lai RWM, Orr WK, Shortridge KF (1999) Human infection with influenza H9N2. Lancet 354:916-917
14. Sokal RR, Rohlf FJ (1995) Biometry. The Principles and Practice of Statistics in Biological Research. Freeman, New York, pp 423-439
15. Sokal RR, Rohlf FJ (1995) Biometry. The Principles and Practice of Statistics in Biological Research. Freeman, New York, pp 686-687
16. Tamblyn SE, Hinman AR (1993) Pandemic planning: Conclusions and recommendations. In: Hannoun C, Kendal AP, Klenk HD, Ruben FL (eds) Options for the Control of Influenza, II. International Congress Series no. 1019. Elsevier, Amsterdam, pp 457-459
17. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG (1997) Initial genetic characterization of the 1918 'Spanish' influenza virus. Science 275:1793-1796
18. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Bluckwelder W, Katz JM (2001) Safety and immunogenicity of a recombinant vaccine for H5 influenza in humans. Vaccine 19:1732-1737
19. WHO (1999) Influenza Pandemic Preparedness Plan. Responding to an Influenza Pandemic or its Threat: The Role of WHO and Guidelines for National or Regional Planning. World Health Organization, Geneva
20. WHO Collaborating Centers for Reference and Research on Influenza (1982) Concepts and Procedures for Laboratory Based Influenza Surveillance. WHO CCRRI, CDC, Atlanta
21. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SHW, Karzan DT (1977) Trials of influenza A/New Jersey/76 virus vaccine in normal children - An overview of age-related antigenicity and reactogenicity. J Infect Dis 136:731-741